Pharma-Bio Serv, Inc. (PBSV) stock
Close on Oct 19, 2026Market cap $11.00MP/E 48.0Yield –
Pharma-Bio Serv, Inc. grew revenue 3.3% to $9.48M over the twelve months to Jul 31, 2026. Free cash flow was -$421.36K. At the latest close the market valued the company at $11.00M, 48.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jul 31, 2026
Valuation
- Market cap
- $11.00M
- P/E ratio
- 48.0
- Price to sales
- 1.16
- Price to book
- 1.05
- Dividend yield
- –
- Free cash flow yield
- -3.83%
Fundamentals
- Revenue
- $9.48M
- Net income
- $251.53K
- EPS, diluted
- $0.01
- Free cash flow
- -$421.36K
- Book value per share
- $0.46
- Diluted shares
- 23M
Trading
- Next earnings
- Jan 28, 2027 (estimated, during market hours)
- Previous close
- $0.40
- Open
- $0.48
- Day's range
- $0.48 – $0.48
- Volume
- 500
- Average volume (20 days)
- 9,525
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | PBSV | S&P 500 | Difference | PBSV per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +4.3% | +0.6% | +3.7 pts | ||
| 3 months | -4.0% | +3.4% | −7.4 pts | ||
| Year to date | -8.3% | +13.3% | −21.6 pts | ||
| 1 year | -10.2% | +16.6% | −26.8 pts | ||
| 3 years | -23.0% | +86.4% | −109.4 pts | -8.4% | +23.1% |
| 5 years | -14.5% | +81.9% | −96.3 pts | -3.1% | +12.7% |
| 10 years | +11.2% | +318.9% | −307.6 pts | +1.1% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Pharma-Bio Serv filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Pharma-Bio Serv
Services-Management Consulting Services
Pharma-Bio Serv provides technical compliance, regulatory affairs, quality, validation, engineering, project management, and technology transfer consulting services. Its business operates across three reportable segments: Puerto Rico technical compliance consulting, United States technical compliance consulting, and Europe technical compliance consulting. The firm serves clients in diverse regulated sectors, focusing on the pharmaceutical, biotechnology, chemical, medical device, cosmetic, and food manufacturing industries.
Company profile, executives and historyPharma-Bio Serv stock: common questions
What is Pharma-Bio Serv's stock price?
PBSV closed at $0.48 on Oct 19, 2026, up 20.00% on the day.
What is Pharma-Bio Serv's market cap?
Pharma-Bio Serv was worth $11.00M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is PBSV's P/E ratio?
PBSV trades at 48.0 times earnings, based on diluted earnings per share of $0.01 over the twelve months to Jul 31, 2026.
How much revenue does Pharma-Bio Serv make?
Pharma-Bio Serv reported revenue of $9.48M for the twelve months to Jul 31, 2026, up 3.3% from a year earlier.
Does Pharma-Bio Serv pay a dividend?
No. Pharma-Bio Serv has not paid a cash dividend over the last twelve months.
When does Pharma-Bio Serv report earnings next?
Pharma-Bio Serv is expected to report Q4 FY2026 results on Jan 28, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has PBSV stock performed over the past year?
Including dividends, PBSV returned -10.2% over the past year, against +16.6% for the S&P 500.
Who are Pharma-Bio Serv's competitors?
Companies most similar to Pharma-Bio Serv by business, industry and size include RYOJ, RTB, ROMA, EGG, ACCL.
See a number that looks wrong?